Route 92 Medical receives Australian Therapeutic Goods Administration approval for its portfolio of neurovascular interventional products.
Neuro
Octane’s First ‘Neuro Tech Forum’: Cutting-Edge Innovations and Global Leaders Converge in Newport Beach, April 2025
Octane’s Premier Event Unites Global Stakeholders and Spotlights Innovations in Neuroscience and Technology for a Day of Breakthrough Insights and Networking – Tickets Still Available NEWPORT BEACH, Calif., March 17, 2025 /PRNewswire/ — Excitement is building for April 4, 2025 as Octane, Southern California’s premier accelerator for medtech innovation, prepares to host the inaugural Neuro Tech Forum at […]
Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment
More than 25,000 Devices Implanted Worldwide from 2010-20251 ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ — Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEB™…
Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA® in Treating Large Hemispheric Infarction, Including Wake-Up Strokes
NEW YORK, March 18, 2025 /PRNewswire/ — Remedy Pharmaceuticals, a leader in stroke drug development, today announced that the U.S. Patent and Trademark Office (USPTO) has allowed two additional patents covering its large hemispheric infarction (LHI) drug, CIRARA (IV glyburide). The…
Growing Market Applications, Centerline Biomedical Granted FDA 510(k) Clearance for IOPS® with New, Expanded Indication for Use
CLEVELAND–(BUSINESS WIRE)–Centerline Biomedical, Inc. (“Centerline”), an innovative leader in cardiovascular navigation and visualization systems, announced that the company has received US Food and Drug Administration (FDA) 510(k) clearance of expanded indications for its Intra-Operative Positioning System (IOPS). This news is complemented by the recent 510(k) clearance of the IOPS Fiducial […]
MicroTransponder Secures $65 Million to Enhance Vivistim Adoption for Chronic Stroke Recovery
AUSTIN, Texas, March 12, 2025 /PRNewswire/ — Announcing a $65 million Series F financing round, MicroTransponder®, Inc., one of the fastest-growing stroke companies, is transforming the stroke continuum of care with its FDA-approved Vivistim® Paired VNS™ System. The round was led by US…
Enspire DBS Therapy Announces the First Patient Implanted in the Second Center for RESTORE, a Multicenter Pivotal Phase 2/3 Clinical Trial for the Treatment of Arm Weakness and Reduced Function after Stroke
The first patient implanted at Brown University Health marks the expansion of the study to multiple clinical sites RESTORE aims to generate the data necessary to demonstrate the long-term safety and efficacy of DBS+Rehab in stroke patients to support marketing approval CLEVELAND, March 4,…
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients. NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients.
Brainomix Partners with Medtronic to Enhance Stroke Care Across Western Europe
OXFORD, England, Feb. 27, 2025 /PRNewswire/ — Brainomix, a pioneer in stroke AI imaging software and European market leader, has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology. The collaboration aims to enhance stroke care for…
Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River™ Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)
Publication in the Journal of NeuroInterventional Surgery Reports Outcomes for Treatment of IIH Patients Who Are Refractory or Intolerant to Medications Publication in the Journal of NeuroInterventional Surgery Reports Outcomes for Treatment of IIH Patients Who Are Refractory or Intolerant to Medications
Recent
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
MiRus Siegel™ TAVR: First EFS Cases
LifeTech Scientific Corporation Announced 2024 Annual Results: Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%
Popular
- No commented posts yet